Table 3

Antibody prevalence (%) among cases and controls and associated ORs for invasive cervical cancer by different serological tests for HPV-16

Antibody toCases (%), n = 194Controls (%), n = 217ORa (95% CI)
HPV-16 VLP92 (47.4)53 (24.4)2.8 (1.8–4.3)
HPV-16 E6105 (54.1)13 (6.0)18.5 (9.5–36.6)
HPV-16 E759 (30.4)10 (4.6)9.1 (4.3–19.6)
E6 or E7123 (63.4)22 (10.1)15.4 (9.8–27.0)
E6 and E741 (21.1)1 (0.5)57.9 (8.4–1145)
E6 or E7 or VLP156 (80.4)68 (31.3)9.0 (5.6–14.6)
E6 and E7 and VLP20 (10.3)1 (0.5)24.8 (3.5–502)
  • a ORs are crude.